U.S. Herpes Zoster Market Size, Share & Forecast 2026–2032

ID: MR-11327 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Herpes Zoster Market
  • ✓Market Size 2024: USD 6.2 billion
  • ✓Market Size 2032: USD 9.4 billion
  • ✓CAGR: 5.3%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Shingrix faces pharmacy-led erosion: GSK's Shingrix controls the U.S. zoster vaccine category, but CVS Health and Walgreens Boots Alliance increasingly determine which doses are stocked and reimbursed. Retail chains now act as gatekeepers, so GSK's future share depends on pharmacy contracting as much as clinical differentiation.
FINDING 02
Generics are not commoditized: The common assumption holds that generic valacyclovir is a pure price market. Supply reliability is the decisive factor, because intermediate shortages and wholesale distributor consolidation are shifting share toward Viatris, Teva and Aurobindo suppliers with resilient U.S. manufacturing footprints.
ANALYST RECOMMENDATION

Analyst Recommendation — Lock pharmacy contracts early: Vaccine suppliers and generic manufacturers should secure multi-year agreements with CVS Health, Walgreens Boots Alliance and major pharmacy benefit managers before the 2026 Medicare Part D formulary cycle. Early commitment protects share as payer rebate pressure intensifies and challenger entry approaches.

Shingles Competitive Overview in the U.S.

The U.S. zoster market operates as two distinct tiers. In prescription vaccines, GSK's Shingrix holds near-total share of new vaccinations since Merck withdrew Zostavax in 2020, creating a single-brand category with a pricing-disciplined incumbent. Antiviral treatment is the opposite: generic valacyclovir from Viatris, Teva and Aurobindo dominates volume, while branded Valtrex retains only a residual share, so concentration is high in vaccines and fragmented in generics.

Domestic players gain advantage less from manufacturing scale than from channel control. CVS Health and Walgreens Boots Alliance administer large volumes of adult zoster doses through retail clinics and pharmacy-led immunization programs, making pharmacy access and immunizer credentialing decisive. International multinationals compete through formulary contracting with pharmacy benefit managers, while Moderna's mRNA pipeline positions it as the most credible future challenger in the vaccine tier.

Demand Drivers Shaping U.S. Shingles Prevention and Treatment

Three country-specific drivers shape demand. First, the CDC's recommendation of Shingrix for all adults aged 50 and older, adopted in 2022, expanded the eligible population to more than 100 million Americans and favors GSK's established immunization infrastructure. Second, the Inflation Reduction Act removed Medicare Part D cost-sharing for ACIP-recommended adult vaccines from 2023, which benefits retail pharmacies that capture Part D volume.

Third, an ageing population and rising use of immunosuppressive therapies expand the at-risk pool. Players with dedicated patient-support programs and specialty distribution gain most from this shift, particularly GSK and specialty pharmacies. Generic antiviral makers benefit from sustained treatment volumes among uninsured and cash-paying patients, where price rather than brand determines prescribing decisions.

Competitive Restraints and Market Challenges

Price competition is intensifying at the vaccine tier as pharmacy benefit managers demand larger rebates for Shingrix placement, and as Medicare negotiation exposure grows. Generic valacyclovir erodes margins for Viatris, Teva and Aurobindo, where prices have fallen steadily and gross margins remain thin, pushing smaller manufacturers toward exit and rewarding scale producers.

Regulatory compliance costs and supply constraints raise entry barriers. Biologics require FDA Biologics License Application review and Center for Biologics Evaluation and Research oversight, while cold-chain logistics and immunizer staffing limit capacity at independent clinics. Shortages of pharmacists and nurses authorized to administer vaccines further constrain how quickly retail chains can extend their reach.

Growth Opportunities for Market Players

Moderna's mRNA zoster candidate and Curevo's amezosvatein represent pipeline-stage challengers targeting a next-generation zoster vaccine. Firms that secure late-stage partnerships and U.S. manufacturing commitments will be positioned to contest Shingrix's near-monopoly, and those that move first on licensure will capture the earliest payer contracts.

Pharmacy-led vaccination and employer-sponsored programs offer distribution opportunities. CVS and Walgreens are expanding immunization services into rural and underserved zip codes, while employer health plans represent an underused channel for adult vaccination. Players that align pharmacist training with payer contracting can capture incremental doses without adding manufacturing capacity.

Market at a Glance

MetricDetail
Market Size 2024USD 6.2 billion
Market Size 2032USD 9.4 billion
Growth Rate (CAGR)5.3%
Most Critical Decision FactorPharmacy benefit manager formulary placement and payer contracting
Largest RegionSouth region
Competitive StructureConcentrated in vaccines; fragmented in generic antivirals

Leading Market Participants

  • GSK
  • Viatris
  • Teva Pharmaceutical
  • Aurobindo Pharma
  • Sandoz
  • Zydus Pharmaceuticals
  • Moderna
  • Curevo
  • CVS Health
  • Walgreens Boots Alliance

Regulatory and Policy Environment

The FDA's Center for Biologics Evaluation and Research licenses zoster vaccines, while the FDA's Office of Generic Drugs governs antiviral generics under Hatch-Waxman provisions. ACIP sets recommendations that trigger no-cost coverage under Affordable Care Act preventive services requirements for commercially insured adults, shaping which products payers will reimburse.

The Inflation Reduction Act's Part D redesign and drug price negotiation program reshape competitive economics. Section 11401 eliminated Part D cost-sharing for ACIP-recommended adult vaccines from 2023, while the Medicaid Drug Rebate Program and 340B pricing rules govern net prices for antivirals. Orange Book patent listings determine when generic valacyclovir entrants can launch.

Competitive Outlook for U.S. Shingles

By 2032, the vaccine segment will shift from a single-brand market toward a duopoly if an mRNA zoster product achieves licensure. GSK will retain majority share through its installed base and pharmacy contracts, but its share of new doses will erode as challengers secure payer access and pharmacy listings.

Antiviral generics will remain concentrated among three to four manufacturers with cost-leading supply chains, while retail chains consolidate purchasing power. Winners will combine pipeline credibility, payer contracting depth and pharmacy access, and price competition in generics will persist through the forecast period.

Frequently Asked Questions

GSK's Shingrix holds near-total share of new zoster vaccinations in the U.S. following Merck's withdrawal of Zostavax in 2020. Its position rests on ACIP recommendations and established pharmacy contracts.
Viatris, Teva and Aurobindo compete on price for generic valacyclovir, which keeps margins thin. Scale manufacturers with resilient supply chains hold an advantage over smaller entrants.
CVS Health and Walgreens Boots Alliance control stocking, immunizer staffing and formulary input for many retail doses. Their contracting decisions directly shape which products reach patients.
Moderna and Curevo are the most advanced pipeline challengers targeting next-generation zoster vaccines. Their success depends on licensure timing and payer access.
The Inflation Reduction Act removed Part D cost-sharing for ACIP-recommended adult vaccines from 2023. This change favors products with broad recommendations and strong pharmacy distribution.

Market Segmentation

By Product Type
  • Recombinant Adjuvanted Zoster Vaccine
  • Valacyclovir
  • Famciclovir
  • Acyclovir
By Distribution Channel
  • Retail Pharmacies
  • Hospital Pharmacies
  • Mail-Order Pharmacies
  • Physician Offices
  • Mass Vaccination Programs
By End User
  • Adults 50 and Older
  • Immunocompromised Adults
  • Long-Term Care Facilities
  • Outpatient Clinics

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Herpes Zoster Market - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Product Type Insights
4.1 Recombinant Adjuvanted Zoster Vaccine
4.2 Valacyclovir
4.3 Famciclovir
4.4 Acyclovir
4.5 Others
Chapter 05 Distribution Channel Insights
5.1 Retail Pharmacies
5.2 Hospital Pharmacies
5.3 Mail-Order Pharmacies
5.4 Physician Offices
5.5 Others
Chapter 06 End User Insights
6.1 Adults 50 and Older
6.2 Immunocompromised Adults
6.3 Long-Term Care Facilities
6.4 Outpatient Clinics
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 GSK
7.2.2 Viatris
7.2.3 Teva Pharmaceutical
7.2.4 Aurobindo Pharma
7.2.5 Sandoz
7.2.6 Zydus Pharmaceuticals
7.2.7 Moderna
7.2.8 Curevo
7.2.9 CVS Health
7.2.10 Walgreens Boots Alliance
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.